Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00161057
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : April 23, 2009
Sponsor:
Information provided by:
UMC Utrecht

Brief Summary:
In this study we, the investigators at UMC Utrecht, intend to investigate changes in brain activation patterns using functional magnetic resonance imaging (MRI), in patients suffering from schizophrenia who are medication naive or off medication, before using medication and after 8 weeks of medication. Patients will perform a working memory task, a language task and a motor task while lying in the scanner. We hypothesize that the efficiency of the working memory system is reduced and that the lateralization of language is diminished in these patients, and that these functions will normalize after treatment.

Condition or disease
Schizophrenia Schizophreniform Disorders

Detailed Description:

Schizophrenia is a heterogeneous disorder with a wide range of symptoms and signs including hallucinations, delusions, disorganisation, negative symptoms and cognitive deficits. Investigation of the neural substrates of the cognitive deficits in schizophrenia has revealed abnormalities in brain activity patterns. Particularly, earlier studies using functional FMRI conducted at the UMCU, revealed diminished language laterality, deficits in working memory and a reduced ability to automate cognitive processes. The aim of this project is to study the relationship between these brain activation patterns and neuroleptic treatment. More insight into psychopharmacological effects on brain physiology, may eventually enable us to better predict what effect treatment will have on patients.

Patients with a confirmed diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder not otherwise specified (NOS), who are medication naive or medication free for a period of at least 2 weeks will be included. Patients will be tested before and after 8 weeks of treatment with an atypical antipsychotic. In the scanner patients will perform a working memory task, a language task and a visual-motor task. At study entry and after 8 weeks the PANSS, Clinical Global Impressions (CGI) and CDSS (Calgary Depression Scale of Schizophrenia) will be performed. Besides these patients, we will also include a group of matched healthy controls. We hypothesize that in medication naive or patients of-medication lateralization is reduced, and that efficiency of the working memory system is reduced. Lateralization is expected to correlate negatively with positive functions. We expect that antipsychotic treatment will normalize brain function and that the degree of normalization is correlated with the clinical measures of treatment efficacy.

Layout table for study information
Study Type : Observational
Actual Enrollment : 78 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment
Study Start Date : December 2001
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
first episode schizophrenia patients, medication naive (or medication-free) and matched healthy controls.
Criteria

Inclusion Criteria (patients):

  • Diagnoses of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS, confirmed on the basis of Comprehensive Assessment of Symptoms and History (CASH) or a Structured Clinical Interview for DSM-IV Disorders (SCID) interview
  • Ages between 16 and 50 years
  • CGI of at least 4
  • Patients are neuroleptic-naive or medication-free for at least 2 weeks

Inclusion Criteria (healthy controls):

  • No psychiatric disorders (according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition [DSM-IV], Axis I)
  • No psychiatric disorders in first degree relatives.
  • Ages: between 18 and 50 years old

Exclusion Criteria (patients and healthy controls):

  • Ferrous objects in or around the body
  • Neurological or medical illness, including closed head injury.
  • Mental retardation.
  • Diagnosis of substance dependence within the previous 3 months.
  • Pregnancy
  • Treatment with antidepressants or mood stabilizers within 3 weeks of inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00161057


Locations
Layout table for location information
Netherlands
Dept. of Psychiatry, UMC Utrecht
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
UMC Utrecht
Investigators
Layout table for investigator information
Principal Investigator: Nicoletta V Veelen UMC Utrecht
Study Chair: Rene Kahn, M.D. Ph.D. UMC Utrecht
Layout table for additonal information
Responsible Party: divisie hersenen, UMC Utrecht
ClinicalTrials.gov Identifier: NCT00161057    
Other Study ID Numbers: METC 01/134
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: April 23, 2009
Last Verified: April 2009
Keywords provided by UMC Utrecht:
Schizophrenia
Medication-naive
Functional MRI
Working memory
Language lateralization
schizoaffective disorder
psychotic disorder Not Otherwise Specified
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders